Want obesity drugs covered by insurance — 2026-06-14 cover art

Want obesity drugs covered by insurance — 2026-06-14

Want obesity drugs covered by insurance — 2026-06-14

Listen for free

View show details
## Short Segments People taking GLP-1 weight loss drugs like Ozempic are moving less, according to new research. Middle-aged Americans are facing a crisis of loneliness and declining health. And a surprising study finds that sugar-free diets might not be as healthy as they seem. Later, we'll explore how telehealth companies are influencing insurance coverage for obesity drugs. People taking GLP-1 weight loss drugs like Ozempic started moving less. Researchers have found that individuals on popular weight-loss medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are experiencing a decline in physical activity. Despite shedding pounds, Fitbit data reveals a drop in daily step counts and exercise levels. This trend raises concerns because these drugs can reduce muscle mass along with fat, potentially impacting long-term health and strength. The findings suggest that while these medications are effective for weight loss, they may inadvertently discourage other healthy habits, highlighting the need for a balanced approach to weight management. Why middle age is becoming a breaking point in the U.S. A new international study highlights a troubling trend among middle-aged Americans, who are reportedly lonelier, more depressed, and experiencing worse memory and health compared to previous generations. Researchers attribute these issues to growing financial strain, weaker social supports, and chronic stress. This demographic is increasingly seen as a pressure point, with the U.S. falling behind other wealthy nations in terms of midlife well-being. The study underscores the need for targeted interventions to address these challenges and improve the quality of life for middle-aged individuals. Scientists found a surprising problem with sugar-free diets. A recent study suggests that completely eliminating sugar from the diet may have unintended negative effects. Mice on a sucrose-free, low-fat diet showed worse blood sugar control, increased inflammation, and signs of fatty liver compared to those consuming some sucrose. These findings indicate that a balanced diet and a healthy gut microbiome are crucial, rather than focusing solely on cutting out sugar. The research challenges the common perception that sugar-free diets are inherently healthier, emphasizing the importance of moderation and balance in dietary choices. ## Feature Story Want obesity drugs covered by insurance? Telehealth companies have a big say. Telehealth companies are playing a pivotal role in the coverage of obesity drugs by insurance providers. Employers are increasingly relying on these companies to offer lifestyle support for individuals taking GLP-1 medications, such as Zepbound, to enhance weight loss success. However, there's a catch: employers also expect telehealth providers to help limit spending on these costly drugs. This dual role creates a complex dynamic where patients like David Davis, a power plant worker from California, find themselves navigating a maze of requirements to get their prescriptions approved. Davis's experience with Vida Health, a telehealth company, highlights the frustration many face as they jump through hoops to access necessary treatments. The involvement of telehealth companies in this process reflects a broader trend in the healthcare sector, where digital health entities are capitalizing on the popularity of GLP-1 medications. As these drugs become more prevalent, the pressure on telehealth companies to manage costs while providing effective support is likely to increase. This situation underscores the evolving landscape of healthcare delivery and the growing influence of telehealth in shaping treatment accessibility. As the demand for obesity drugs continues to rise, the role of telehealth companies in determining insurance coverage will be a critical area to watch.
adbl_web_anon_alc_button_suppression_t1
No reviews yet